These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28093483)

  • 21. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
    Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19808. PubMed ID: 25397552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
    Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
    BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
    Honda M; Ishisaka M; Ishizuka N; Kimura S; Oka S;
    Intern Med; 2011; 50(7):699-705. PubMed ID: 21467701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    PLoS One; 2014; 9(5):e96187. PubMed ID: 24825167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
    Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
    HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
    Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
    Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
    PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
    Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
    Blanco JL; Rojas J; de Lazzari E; Inciarte A; Subirana M; Callau P; Martinez-Rebollar M; Laguno M; Mallolas J; de la Mora L; Torres B; Gonzalez-Cordón A; Martinez E
    J Antimicrob Chemother; 2022 Jun; 77(7):1974-1979. PubMed ID: 35512339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
    Haas DW; Zala C; Schrader S; Piliero P; Jaeger H; Nunes D; Thiry A; Schnittman S; Sension M;
    AIDS; 2003 Jun; 17(9):1339-49. PubMed ID: 12799555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
    Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
    Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
    Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
    Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.